Intravenous immunoglobulin in the therapy of systemic vasculitis
Transfusion Science, ISSN: 0955-3886, Vol: 13, Issue: 3, Page: 317-324
1992
- 8Citations
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
The current therapy of the systemic vasculitides with corticosteroid and cytotoxic drugs is successful in controlling disease in the majority of patients but is limited by adverse effects; drugs must also be continued in the long-term as relapse frequently follows their withdrawal. Autoantibodies to neutrophil cytoplasmic antigens (ANCA) are associated with systemic vasculitis and have been implicated in its pathogenesis. Interest in the use of pooled immunoglobulin (IVIg) in the therapy of vasculitis has followed the detection of antiidiotype antibodies to ANCA in IVIg and the success of IVIg in the treatment of Kawasaki disease, an ANCA positive childhood vasculitis.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/0955388692901424; http://dx.doi.org/10.1016/0955-3886(92)90142-4; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0026704292&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/0955388692901424; http://dx.doi.org/10.1016/0955-3886%2892%2990142-4; https://dx.doi.org/10.1016/0955-3886%2892%2990142-4
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know